TY - JOUR
T1 - Translating efficacy into effectiveness in antiretroviral therapy
T2 - Beyond the pill count
AU - Fletcher, Courtney V.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2007
Y1 - 2007
N2 - Durable and sustained suppression of HIV replication can be achieved as demonstrated in several recent clinical trials of antiretroviral (ARV) regimens. However, the efficacy demonstrated in the experimental setting does not always translate to effectiveness in the clinical setting. The frequency and number of medications (conventionally referred to as the pill count) contribute to regimen effectiveness. However, clinicians and HIV-infected patients recognise that there are several other characteristics of an ARV regimen that are equally important contributors to its effectiveness. Potency and durability, the potential for drug-drug interactions, and the occurrence of adverse events also contribute to the effectiveness and complexity of a drug regimen. A comprehensive consideration of factors associated with efficacy will optimise the translation to effectiveness for the individual infected with HIV.
AB - Durable and sustained suppression of HIV replication can be achieved as demonstrated in several recent clinical trials of antiretroviral (ARV) regimens. However, the efficacy demonstrated in the experimental setting does not always translate to effectiveness in the clinical setting. The frequency and number of medications (conventionally referred to as the pill count) contribute to regimen effectiveness. However, clinicians and HIV-infected patients recognise that there are several other characteristics of an ARV regimen that are equally important contributors to its effectiveness. Potency and durability, the potential for drug-drug interactions, and the occurrence of adverse events also contribute to the effectiveness and complexity of a drug regimen. A comprehensive consideration of factors associated with efficacy will optimise the translation to effectiveness for the individual infected with HIV.
KW - Antiretrovirals, therapeutic use
KW - HIV infections, treatment
KW - Lopinavir/ritonavir, therapeutic use
UR - http://www.scopus.com/inward/record.url?scp=34948875339&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34948875339&partnerID=8YFLogxK
U2 - 10.2165/00003495-200767140-00001
DO - 10.2165/00003495-200767140-00001
M3 - Review article
C2 - 17883282
AN - SCOPUS:34948875339
SN - 0012-6667
VL - 67
SP - 1969
EP - 1979
JO - Drugs
JF - Drugs
IS - 14
ER -